Recently, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. (hereinafter referred to as "Novatim") announced that it has completed its first round of financing with a scale of nearly 500 million yuan, invested by Ke Quan Fund established in the Anji Development Zone of Zhejiang Province. The funds will be mainly used for clinical trials of core products, IND application for core pipelines, and construction of GMP factories.
Dr. Wu Guoxiang, the founder, stated that after this round of financing, the company will accelerate the clinical trials and IND application of its core products, speed up the commercialization process of its innovative tumor immunotherapy drugs, continuously develop tumor immunotherapy products with global competitive advantages, and lay a phased foundation for the company to grow into a respected global leading innovative drug research and development company.
Novatim
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. was established in 2018. It is a biopharmaceutical technology enterprise specializing in the research and clinical application of innovative drugs for tumor immunotherapy. It wholly owns
Shanghai Tinova Immune Therapeutics Co., Ltd. (focused on the research and clinical application of the new generation of CAR-T). Based on clinical needs and its focus on tumor immunotherapy, the company has established R&D platforms for dual-function antibodies, dual-antibody ADC, solid tumor CAR-T, and hematological tumor CAR-T, and has developed 10 FIC/BIC products.
Research and development progress
The company independently developed the first domestic targeted PD-1 mutant IL-2 fusion protein - KY-0118 injection. This product was approved by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) in August this year to start clinical trials. It is expected to complete the first patient enrollment in November this year. Its unique design concept has played the role of a new-generation agonist. It is known that the development progress of this product in the same field ranks second globally, only after Roche. It has obtained a number of international and domestic patents.
